… patients with pre-existing neurological diseases, such as dementia, … neurological disorders (p = 0.033) were more prevalent in patients who developed … “All” (treat all patients) and “None” (treat no patients) … : a randomised controlled trial. Eur J Anaesthesiol. …

… developer Sanofi revealing that the US Food and Drug Administration (FDA) … tolebrutinib’s approval to treat non-relapsing secondary … a form of the neurological disease where disability steadily … the parent company of Pharmaceutical Technology. The French …

… protein that damages neurons. Trial data, released but … advancement three years after treatment, measured via combined … Drug Administration in early 2026, targeting to introduce the treatment … disease is a hereditary neurological disorder that damages brain …

… revolutionary breakthrough in treating Huntington… this fatal inherited neurological disorder. The innovative … -patient trial data, released by pharmaceutical company … uniQure, demonstrates sustained benefits three years post-treatment …

… most prevalent and disabling neurological disease, but the current pharmacotherapies show limited efficacy … mechanism involved. A randomized controlled trial was performed among 10 normal … to two courses of treatment, and each treatment lasted for 5 days …

… and Drug Administration (USFDA), has been introduced in India. Developed by … it right now. This FDA-approved test bridges that gap … and differentiate it from other neurological disorders. If your value is … you are predisposed to developing Alzheimer’s. This is …

… placebo control. Double-blind treatment continued for 60 weeks … progressive and often fatal neurological disease that afflicts one patient … GFAP gene. Zilganersen treats the condition by reducing … The FDA has previously granted zilganersen its orphan drug and …

… rare and often fatal neurological disease. Based on the findings … first time that a medication showed positive disease- … our technology to address neurological diseases by directly targeting the … the trial concludes with a 28-week post-treatment follow- …

… to metabolic and even neurological disorders, opening new therapeutic … this understanding by treating drug delivery not as … Unlike conventional drugs with fixed pharmacological properties, adaptive … the development of evidence based regulatory frameworks (FDA, …

… as those who take specific medications. People living with chronic diseases … and drive poor thermoregulation include: Neurological diseases, including Parkinson’s and Multiple … to a higher risk of developing adverse reactions to extreme temperatures …